![]() |
|
|
Vol. 31, Issue 4, 447-451, April 2003
Merck Frosst Centre for Therapeutic Research and Co., Montréal, Québec, Canada (R.H., J.R., J-F.L., D.A.N.-G., J.M.S.); Departments of Pharmaceutical Sciences and Pharmacology, University of Toronto, Toronto, Ontario, Canada (K.S.P.); Department of Pharmacology, Dalhousie University, Nova Scotia, Canada (J.R.)
| |
Abstract |
|---|
|
|
|---|
The success of cryopreservation of isolated hepatocytes with
existing methodologies is assessed with respect to the retentivity of
cell integrity/viability (defined by trypan blue) and metabolic activities upon thawing in comparison to those of freshly prepared cells. But the ability of the cryopreserved cells to transport xenobiotics relative to that of freshly prepared cells has not been
investigated. In this study, we optimized our previous methodology for
cryopreservation and evaluated the metabolism and transport of thawed
hepatocytes. Half of the freshly, isolated rat hepatocytes prepared by
collagenase perfusion were immediately used for studies of transport of
[14C]taurocholate, [3H]estrone sulfate and
[3H]estradiol 17
-D-glucuronide (1 µM)
and metabolism of 7-hydroxy-4-(trifluoromethyl)-coumarin (100 µM),
(3,4-difluorobenzyloxy)-5,5-dimethyl-4-(4-methylsulfonylphenyl)-(5H)-furan-2-one (250 µM), bufuralol (100 µM), and tolbutamide (100 µM), probes for UDP-glucuronyl transferase (UGT) and CYP3A, CYP2D, and CYP2C, respectively. The remaining half was cryopreserved using an optimized, programmed-freezing protocol, which was developed to minimize the
prolonged release of latent heat during freezing. With the exception of
the UGT probe, no significant difference (P > 0.05) was found in both metabolism and transport with freshly isolated versus cryopreserved hepatocytes upon thawing. In conclusion, we have
demonstrated for the first time that thawed rat hepatocytes cryopreserved by a programmed-freezing protocol retain drug transport activities.
| |
Introduction |
|---|
|
|
|---|
Drug transport across the
hepatocyte plasma membranes is a key factor in hepatic clearance.
Hepatobiliary transport of endogenous and exogenous compounds is
mediated by the co-ordinated action of multiple transport systems
present at the sinusoidal (basolateral) and canalicular (apical)
membrane domains of hepatocytes. The lipophilic properties of drugs
enable them to cross the sinusoidal membrane by passive diffusion.
However, for others, entry into the hepatocyte can be facilitated via a
variety of sinusoidal transporters that augment passive diffusion. Such
drugs with molecular weights >400 tend to be hydrophilic since they
usually contain polar groups and are ionized (either anionic or
cationic) (Meijer et al., 1990
; Ayrton and Morgan, 2001
). These drugs
enter the liver by sinusoidal drug transporters, including the
sodium-dependent taurocholate cotransporting polypeptide
(NTCP2) (Hagenbuch
and Meier, 1994
), members of the organic anion-transporting polypeptide
(OATP) (Bossuyt et al., 1996
; Cattori et al., 2001
), and the organic
cationic transporter (Gründemann et al., 1994
). Biliary
elimination of drugs is mediated by different ATP-binding cassette-transporters as exemplified by the multidrug-resistance P-glycoprotein (MDR1, MDR2) for neutral and cationic compounds (Meijer
et al., 1997
), and the canalicular multi-drug resistance-associated transporter (MRP2) (Payen et al., 2000
) for anionic and conjugated drugs.
In our laboratory, rat and human hepatocytes have been routinely used
for studies related to hepatic metabolism and transport of xenobiotics.
For transport studies, freshly isolated hepatocytes have been used to
investigate drug uptake to determine the role of transporters in the
overall drug disposition by the liver (Tan et al., 1999
; Abu-Zahra et
al., 2000
; Kusuhara and Sugiyama, 2002
; Meng et al., 2002
). To this
effect, freshly isolated rat hepatocytes have been commonly used since
several reports have demonstrated good correlation between results
obtained with rat hepatocytes with those from perfused liver and whole
animal studies (Tan et al., 1999
; Abu-Zahra et al., 2000
; Kusuhara and
Sugiyama, 2002
). One of the limitations of this technique is the
requirement for isolation of cells from fresh tissue every time an
experiment is to be conducted. Another major hurdle is the scarcity of
liver tissue available for some species, especially human.
It would be highly desirable if daily preparation could be avoided.
This may be achieved by cryopreservation of surplus hepatocytes after
isolation so that they can be stored for use when needed. We and others
have already demonstrated that cryopreserved hepatocytes retain
metabolic capacities that are comparable with freshly prepared cells
(Zaleski et al., 1993
; Steinberg et al., 1999
; Silva et al., 1999
).
Although cryopreserved hepatocytes may be used and are suitable for
drug metabolism studies, the transport of drugs within cryopreserved
hepatocytes has not been reported (Kusuhara and Sugiyama, 2002
). In
this study, we further improved and optimized the cryopreservation
methodology of rat hepatocytes to attain cells with drug transport
capacities comparable with fresh cells. We furthered assessed whether a
controlled freezing procedure would improve cell yield over a two-stage
freezing protocol. Hengstler et al. (2000)
have recently
reported that a controlled slow-freezing protocol with a supercooling
step minimized the release of latent heat and resulted in significant
increases in viable cells after thawing. They reasoned that, as the
temperature decreases and cell mixture began to freeze, crystallization
would start, and the latent heat of fusion would be released resulting
in the warming of the cells mixture. Since freezing and thawing are
damaging to cells, these processes are major hindrances for successful cryopreservation. One way to minimize this phenomena is to supercool the freezing chamber at the moment when the cells are beginning to
freeze to minimize the warming of the cell mixture as latent heat is
being released. This process can be recorded by measuring the
temperature of the cells in the cryovial as well as the temperature in
the freezing chamber. Results from cryopreserved cells by this method
clearly demonstrated that rat hepatocytes thus prepared were useful for
the study of drug transport and metabolism.
| |
Materials and Methods |
|---|
|
|
|---|
Materials.
14C-Dextrancarboxy (6.5 mCi/ml), DMSO,
polyvinyl-pyrrolidone, BSA (35%), trypsin inhibitor, L15
medium Leibovitz, and Krebs-Henseleit buffer were obtained from
Sigma-Aldrich (St. Louis, MO).
Tauro[carbonyl-14C]cholic acid (sodium salt)
54.0 mCi/mmol and Percoll were purchased from Amersham Pharmacia
Biotech Inc. (Baie d'Urfe, QC). Collagenase type 2 was procured from
Worthington Biochemical Corp. (Freehold, NJ). [ 3H]Estrone sulfate (specific activity, 40 Ci/mmol) and [3H]estradiol
17
-D-glucuronide (specific activity 40.5 Ci/mmol) were
obtained from PerkinElmer Life Science Inc. (Boston, MA). n-Butyl phthalate was obtained from Fisher Scientific
(Nepean, ON). Perchloric acid (70%) was purchased at A&C Inc.
(Montreal, QC). All Falcon sterile cell culture labwares were purchased
from Becton Dickinson (Franklin Lakes, NJ).
Isolation of Rat Hepatocytes.
All animal studies were approved by the institution's animal care and
use committee and were conducted in accordance with all applicable
regulation. Rat hepatocytes were isolated from male Sprague-Dawley rats
purchased from Charles River (200-250 g) by a two-step collagenase (70 U/ml) perfusion as described by Moldéus et al. (1978)
.
Viability of freshly isolated hepatocytes was assessed by trypan blue
uptake (0.2%). Hepatocyte preparations with a cell viability <85%
were rejected.
Cryopreservation and Thawing.
Cryopreservation of rat hepatocytes was conducted by two methods. The
first was one described previously (Silva et al., 1999
) and involved a
two-step freezing protocol. The second method employed a controlled
freezing protocol with a programmable freezer (Cryomed system from
Thermo Forma, Marietta, OH). In these methods, freshly isolated
hepatocytes were incubated for 30 min in Krebs-Henseleit buffer
containing 15 mM glucose and 12 mM HEPES, pH 7.4, at 5 × 106 cells/ml in a shaker-water bath at 37°C
under an atmosphere of 95% O2/5%
CO2. Cells were centrifuged and resuspended in
cold L15-media containing 40% fetal bovine serum and 5% BSA, pH 7.4. Then a mixture containing an equal volume of cold L15-media containing 26% DMSO and 4% polyvinyl-pyrrolidone was added slowly (1 ml/min). Cells were transferred into 5-ml cryogenic tubes (Corning, Palo Alto,
CA) and kept on ice for 10 min. For the freezing method of Method 1, the cells were placed at
20°C for 1 h and at
70°C for
another hour before being stored in liquid nitrogen (Silva et al.,
1999
). For Method 2, we furthered assessed whether a controlled freezing procedure would improve over the two-stage freezing protocol of Method 1. A freezing procedure controlled by a Cryomed Programmable freezer (Thermo Forma) was used. That included a slow freezing at
1°C/min until the temperature reached
7°C in the sample, which
is 2°C before the expected freezing point. That was followed by a
supercooling step at
60°C/min to
80°C in the chamber to rapidly
adsorb the release of latent heat. Then the chamber was reheated at
+40°C/min to
20°C, and the freezing process was continued at
1°C/min to
40°C in the chamber. A rapid freezing step at
10°C/min to
90°C in the chamber was done to complete the
freezing Method 2. Cryotubes were then rapidly placed into a liquid
nitrogen storage reservoir and stored for at least 1 week prior to thawing.
Metabolism Studies.
Freshly prepared or thawed, isolated rat hepatocytes (2 × 106cells/ml) were preincubated at 37°C under a
95% O2/5% CO2 atmosphere for 15 min before the addition of substrate.
7-Hydroxy-4-(trifluoromethyl)-coumarin (7-HFC, 100 µM) and
(3,4-difluorobenzyloxy)-5,5-dimethyl-4-(4-methylsulfonylphenyl)-(5H)-furan-2-one (DFB, 250 µM), probes for UGT and CYP3A activity (Chauret et al., 1999
), respectively, were incubated with the cells for 10 min. Bufuralol and tolbutamide (100 µM), probes for CYP2D and 2C (Kronbach et al., 1987
; Miners et al., 1988
), respectively, were incubated with
the cells for 2 h. Each incubation was stopped by addition of an
equal volume of acetonitrile for protein precipitation. Parent
compounds remaining in the incubation mixtures and metabolites were
analyzed with a high-performance liquid chromatography/UV system
equipped with a Waters 717 plus auto-sampler, a Waters 616 pump, a
Waters 600S controller, and a Waters 996 photodiode array detector. The
data were collected and processed by Millenium version 3.20 software
(Waters, Milford, MA).
Transport Studies.
Hepatocytes suspended in Krebs-Henseleit buffer at 2 × 106 cells/ml were preincubated in a shaker-water
bath at 37°C for 30 min under an atmosphere of 95%
O2/5% CO2. The uptake studies were initiated
by the addition of radiolabeled substrate (1 µM final concentration)
to the incubation mixture (1.4 ml final volume); sampling (125 µl)
was performed in duplicates at specified times. The cells were rapidly
separated from the incubation medium by a centrifugation method
described by Fariss et al., 1985
. Briefly, each cell aliquot was added
into an Eppendorf microtube consisting of dibutyl phthalate (400 µl)
layered over 10% perchloric acid (250 µl) and was centrifuged
(14,000 rpm) for 15 s. The top layer was aspirated and a sample of
the perchloric acid layer (150 µl) was removed into a scintillation
vial. Subsequent to the addition of 15 ml of liquid scintillation fluor
(Ready Protein; Beckman Canada, Mississauga, ON), the radioactivity was
determined using a Beckman LS5000CE counter. The volume of adherent,
extracellular fluid that was centrifuged with the cells was determined
by incubating the cells with
[14C]dextran-carboxy (6.5 µCi/ml), and the
associated radioactivity of substrate was subtracted from the sample
incubations. Data are expressed in nanomoles of compound per million of
cells, after conversion of the disintegrations per minute into
nanomoles from the specific activity of the sample.
Calculation and Statistics. The initial velocity was assessed by the linear portion of the plot of the amount accumulated into cells versus time. This occurred within 1 min of the uptake study. Hence, the data points (20, 40, and 60 s) were regressed to provide the initial uptake velocity. All data were presented as the mean ± S.E.M. A Student's t test was used to test for significance.
| |
Results |
|---|
|
|
|---|
Comparison of Methods 1 and 2.
When the hepatocytes were precooled to 4°C and placed at
20°C for
1 h (Method 1), the release of latent heat occurred when the
temperature in the cell mixture reached approximately
9°C with an
increase of temperature of approximately 2°C, as shown in Fig.
1. It took 5 min for the freezing chamber
to absorb the released heat. In contrast, under conditions in which the
rate of freezing was controlled and the cells were supercooled prior to
the freezing point (Method 2), the release of the latent heat was
dramatically minimized (Fig. 1). These conditions were found to be the
ones that resulted in the least increase in temperature during the
freezing process.
|
|
|
Metabolic Studies.
To insure that cryopreserved hepatocytes retained their metabolic
capacity, substrates known to be metabolized by several cyotchromes
P450 (bufuralol, tolbutamide and DFB and UGT (7-HFC) were incubated
with hepatocytes before and after cryopreservation. The parent
remaining after a 2-h incubation period with each probe was determined
in fresh hepatocytes and compared with that observed in cryopreserved
cells. Although not shown, the metabolite profiles of the probes in
fresh and cryopreserved cells were identical. As shown in Fig.
2, there was no significant difference in
the relative metabolism of most of these probes when incubated with fresh versus thawed cryopreserved hepatocytes. Metabolism of 7-HFC was
significantly decreased (p < 0.05) in
cryopreserved hepatocyte compare to freshly isolated cells. About 50%
of the UGT activity was lost following cryopreservation. Reports by
other groups have also demonstrated that hepatocytes lose a part of
conjugative pathways after cryopreservation (Diener et al., 1995
; Madan
et al., 1999
; Steinberg et al., 1999
).
|
Transport Studies.
Upon the admixture of the substrate and cells to result in 1 µM of
substrate (radiolabeled and unlabeled) in 1.4 ml of 2 × 106 cells, aliquots (125 µl) were quickly
removed, and the intracellular concentration determined by a
centrifugation technique. As shown in Fig.
3A, uptake of
[3H]taurocholate into freshly isolated
hepatocytes was rapid and linear within the first minute. The rate of
accumulation was indistinguishable from that obtained with the
cryopreserved hepatocytes obtained upon thawing (Fig. 3A; Table
3). Similarly, the initial rates of uptake for [3H]estrone sulfate and
[3H]estradiol 17
-D-glucuronide
were also not significantly different in fresh cells versus the thawed
cells (Fig. 3, B and C; Table 3). This limited set of results clearly
suggests, for the first time, that cryopreserved hepatocytes retain
their capacity to transport compounds across the plasma membrane.
Furthermore, the transport of these compounds was temperature dependent
and dose-saturating (results not shown), consistent with the mechanism
of an active-transport mechanism. As an example, the
Km and
Vmax of taurocholate uptake were 36 µM and 12.3 nmol/106 cells·min in
freshly isolated cells, and 42 µM and 11.3 nmol/106 cells·min in thawed cryopreserved
(Method 2) cells.
|
|
| |
Discussion |
|---|
|
|
|---|
The isolated hepatocyte system that contains intact membranes
serves as an important, physiologically relevant experimental tool for
uptake studies. Some work has been carried out with human hepatocytes
(Olinga et al., 1998a
,b
) whereas rat hepatocytes are used more
routinely. The preparation is facile (Moldéus et al., 1978
) and
the intact cells contain the entire complement of transporters, including passive permeation and transporter-assisted uptake. The
incubation of drug with freshly isolated suspended hepatocytes is
usually conducted over a short time-frame (usually 1 min) such that the
net uptake rate is mostly influx with little efflux and is
time-independent. Conventional cultured cells tend to rapidly lose
hepatic transport activity (Liang et al., 1993
). Recently, it
has been reported that hepatocytes cultured in collagen-sandwich environment regain polarity and form bile canalicular networks (Liu et
al., 1998
). In this model the billiary efflux transporters such as MRP2
are maintained, however, uptake transporters such as NTCP are
significantly down-regulated (Liu et al., 1999
). In contrast, freshly
isolated hepatocytes are reported to reflect the relative uptake rates
found in vivo (Sandker et al., 1994
; Zhou et al., 1994
). Thus,
cryopreservation poses as a viable alternate procedure for the storage
of human and animal hepatocytes. Cryopreserved hepatocytes have been
shown to retain most of the drug-metabolizing activities (Li et al.,
1999
) as well as inducibility of the drug-metabolizing enzymes (Silva
et al., 1999
; Hengstler et al., 2000
). However, use of cyropreserved
hepatocytes for uptake studies has not been attempted.
We have previously described a technique for cryopreserving rat and
human hepatocytes (Silva et al., 1999
). Our previous, two-step freezing
method (Method 1) demonstrated the importance of allowing freshly
isolated hepatocytes to recover their ATP levels by preincubating the
cells for 30 min at 37°C prior to freezing (Silva et al., 1999
). The
present programmed freezing protocol (Method 2) showed improved
recovery (Table 1) and viability (Table 2). Moreover, similar phase I
metabolic activities were observed (Fig. 2). Although UGT lost 50%
activity, phase II metabolic activity was still observed in
cryopreserved rat hepatocytes (Fig. 2).
More importantly, we demonstrated, for the first time that
cryopreserved hepatocytes retained their ability in drug transport. To
assess the ability of thawed cryopreserved hepatocytes to transport compounds, we focused on three well known substrates of uptake transporters and compared their uptake in thawed cryopreserved hepatocytes to freshly prepared hepatocytes that are shown to retain
functional uptake transporter activities (Kato et al., 1999
). Moreover,
uptake by freshly prepared hepatocytes appears to be predictive of drug
uptake in vivo in the liver (Akhteruzzaman et al., 1999
; Kato et al.,
1999
; Abu-Zahra et al., 2000
). As a starting point for investigation,
the compounds chosen, taurocholate, estrone sulfate, and estradiol
17
-D-glucuronide, are prototypic substrates of NTCP and
members of the OATP family (Hagenbuch and Meier, 1994
; Jacquemin et
al., 1994
; Eckhardt et al., 1999
; Cattori et al., 2001
; Sugiyama et
al., 2002
). No difference in initial transport rate was found (Table
3). However, the transporter functions of the organic anion transporter
and organic cations by organic cationic transporter and those at the
canalicular membrane, namely, P-glycoprotein and bile salt export pump,
within cryopreserved hepatocytes remain unknown, although it is
recognized that upon isolation, internalization of MRP2 occurs
(Roelofsen et al., 1995
).
In conclusion, this study demonstrates optimization in the cryopreservation of hepatocytes with Method 2. Even though cryopreservation still resulted in loss of cells, the majority of cells that survived the freezing and thawing processes appeared metabolically similar, with the exception of UGT, to those of the fresh cells. Furthermore, we also showed for the first time that cryopreserved rat hepatocytes retain drug transport activity after thawing. These preliminary observations rendered confidence for use of the cryopreserved cells in drug metabolism and transport studies. We are currently assessing this methodology to hepatocytes from other species, including human.
| |
Footnotes |
|---|
Received September 3, 2002; accepted January 2, 2003.
1 Present Address: Merck Frosst Centre for Therapeutic Research and Co., P.O BOX 1005 Pointe-Claire-Dorval, QC, Canada, H9R 4P8.
Address correspondence to: Robert Houle, Merck Frosst Canada & Co., P.O. Box 1005, Pointe-Claire-Dorval, Quebec, H9R 4P8, Canada. E-mail: robert_houle{at}merck.com
| |
Abbreviations |
|---|
Abbreviations used are: NTCP, sodium-dependent taurocholate cotransporting polypeptide; OATP, organic anion-transporting polypeptide; MRP2, multi-drug resistance-associated transporter; DMSO, dimethyl sulfoxide; BSA, bovine serum albumin; 7-HFC, 7-hydroxy-4-(trifluoromethyl)-coumarin; DFB, (3,4-difluorobenzyloxy)-5,5-dimethyl-4-(4-methylsulfonylphenyl)-(5H)-furan-2-one; UGT, UDP-glucuronyl transferase.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
H. S. Brown, M. Griffin, and J. B. Houston Evaluation of Cryopreserved Human Hepatocytes as an Alternative in Vitro System to Microsomes for the Prediction of Metabolic Clearance Drug Metab. Dispos., February 1, 2007; 35(2): 293 - 301. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-a. Bi, D. Kazolias, and D. B. Duignan Use of Cryopreserved Human Hepatocytes in Sandwich Culture to Measure Hepatobiliary Transport Drug Metab. Dispos., September 1, 2006; 34(9): 1658 - 1665. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. F. McGinnity, M. G. Soars, R. A. Urbanowicz, and R. J. Riley EVALUATION OF FRESH AND CRYOPRESERVED HEPATOCYTES AS IN VITRO DRUG METABOLISM TOOLS FOR THE PREDICTION OF METABOLIC CLEARANCE Drug Metab. Dispos., November 1, 2004; 32(11): 1247 - 1253. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||